Navigation Links
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
Date:2/19/2013

itioned for sustainable long-term growth," said Paul Bisaro, President and CEO. 

"On a proforma basis for the full-year 2012, we launched more than 1,000 generic products globally, and filed more than 1,500 applications globally.  Our Actavis Pharma pipeline is among the strongest in the industry with over 185 ANDAs on file with the U.S. FDA, including 49 first-to-file opportunities, of which, 33 represent potential exclusive first-to-files."

"In our Actavis Specialty Brands business, we experienced growth from U.S. sales of our key promoted products including Rapaflo®, Crinone®, and Generess® Fe.
We expanded our brand portfolio globally as we launched Rapaflo®, Gelnique®, Androderm® and Oxytrol® in Canada and prepared for launches of key branded products in Latin America.  We continued to record progress in our biosimilar initiatives as we acquired a biosimilar to Herceptin® from Synthon and contributed the product to the Amgen collaboration which includes Herceptin®, Avastin®, Rituxan/MabThera® and Erbitux®. Additionally, rFSH entered into the Phase I clinical program."

In January 2013, we acquired Uteron Pharma SA which adds three near term and three longer term projects to our Women's Health development portfolio," Bisaro continued.

"In 2012, we continued to utilize our strong balance sheet as we issued $3.9 billion in senior unsecured notes and completed a new $1.8 billion term loan facility at favorable rates.  We are focused on repaying our debt and maintaining a strong financial foundation to support strategic growth initiatives within our global businesses," concluded Bisaro. 

Fourth Quarter and Full Year 2012 Business Segment ResultsActavis Pharma Segment InformationThree Months EndedTwelve Months Ende
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
(Date:7/6/2015)... SOUTH SAN FRANCISCO, Calif. , July ... ), a leading global pharmaceutical company, and Oculeve, a ... for dry eye disease, today announced that they have ... Oculeve in an all-cash transaction.  Under the terms of ... million upfront payment and commercialization milestone payments related to ...
(Date:7/6/2015)... -- China Information Technology, Inc. (the "Company" or "CNIT") ... platform, exchange, and big data solutions in ... its mobile app for Healthcare One Pass, ushering in ... devices. The Company jointly hosted the launch ceremony with ... Shenzhen News Net.   The mobile app for ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... ... Anticancer Drug, HOUSTON, ... to families, workplaces and communities, and many,Houstonians are aware of ... the CHRISTUS Stehlin Foundation for,Cancer Research, a nationally recognized leader ...
Journalists and other readers should disregard the news release "Oramed,Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository",OTC:ORMP, issued earlier today. The release was transmitted...
Cached Medicine Technology:Local Research Foundation Achieves Milestone in Fight Against Cancer 2Local Research Foundation Achieves Milestone in Fight Against Cancer 3
(Date:7/7/2015)... ... , ... On May 29, 2015, Health Canada announced that they had registered ... for gluten free oats and foods that contain them as ingredients. , “We are ... to include gluten-free oat products in Canada,” says Frank Massong, VP of Regulatory and ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... announced they have been selected by the Department of Vermont Health Access to ... Medicaid Management Information System (MMIS) and Integrated Contact Center System project. , Vermont ...
(Date:7/6/2015)... ... July 06, 2015 , ... Human ... drug discovery. iPSCs are generated from adult cells, such as blood or skin, ... in the human body. , iPSC-derived cardiomyocytes have proven valuable ...
(Date:7/6/2015)... ... July 06, 2015 , ... University of Pittsburgh Cancer Institute ... thyroid cancer testing to reflect newly available tests that better incorporate personalized medicine into ... to interpret thyroid cancer tests is published in the July issue of the scientific ...
(Date:7/6/2015)... Branford, Connecticut (PRWEB) , ... July 06, 2015 ... ... Aesthetic Medical Practice & Medical Spa industries, announces the return of its complimentary ... the Acara team of aesthetic medical business leaders creates success for their clients ...
Breaking Medicine News(10 mins):Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3
... study has indicated that the culprit to most health threat ... used for cooking and heating. According to the UN 5% ... indoor air pollution. ,This study is based on ... air pollution is the physical, chemical, and biological characteristics of ...
... major new cancer research study that may be the last ... United States to discover the genetic and environmental factors that ... 3 (CPS-3) aims to enroll a geographically and ethnically diverse ... to help pave the way for the next generation of ...
... Eye Institute is seeking to raise glaucoma awareness among Mexican-Americans, ... others, the Casa Grande Valley Dispatch reports. ... with a family history of glaucoma all face a higher ... open-angle glaucoma, the most common form glaucoma. ...
... American Journal of Gastroenterology suggests that smoking may determine ... those who suffer from Crohns disease. Where the ... eventually require surgical treatment. ,In patients who ... the small intestine, rather than the colon, says study ...
... protein called tau helped in the reduction of Alzheimers symptoms ... helping find treatment to a deadly brain disorder, scientists ... California, San Francisco said, If this strategy also works in ... ability" ,The researchers, whose work is published in ...
... substantial advancements and success have led to the current imbalance ... them. The United Network for Organ Sharing (UNOS) coordinates the ... wait time, sensitization and HLA matching. ,When ... at the top of the national list. A recent editorial ...
Cached Medicine News:Health News:American Cancer Society Launches Major New Study 2Health News:American Cancer Society Launches Major New Study 3Health News:Who Receives a Kidney Transplant First? 2
... Split Splint reduces PIP joint or DIP joint ... to put on. Soft gel-lining cushions injured fingers ... begin earlier for faster, more successful therapy results. ... and at night to maintain gains in motion. ...
... FoamWrap Final Flexion Wraps restore full PIP ... or when lost due to arthritic changes. ... foam-lined material hugs the finger to prevent ... restore motion. One size. Sold in packages ...
One splint does it all....
... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
Medicine Products: